USA - NYSEARCA:IBO - US45259L2051 - Common Stock
The current stock price of IBO is 0.5322 USD. In the past month the price decreased by -13.8%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 42.1 | 876.24B | ||
| JNJ | JOHNSON & JOHNSON | 17.92 | 447.95B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.28 | 251.61B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.02 | 242.95B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.62 | 215.33B | ||
| MRK | MERCK & CO. INC. | 9.58 | 210.79B | ||
| PFE | PFIZER INC | 7.69 | 139.92B | ||
| SNY | SANOFI-ADR | 11.21 | 119.42B | ||
| GSK | GSK PLC-SPON ADR | 7.73 | 93.91B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.08 | 94.59B | ||
| ZTS | ZOETIS INC | 19 | 53.40B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 194.14 | 42.92B |
Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.
IMPACT BIOMEDICAL INC
1400 Broadfield Blvd., Suite 130
Houston TEXAS US
Employees: 2
Phone: 15852321500
Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.
The current stock price of IBO is 0.5322 USD. The price decreased by -0.13% in the last trading session.
IBO does not pay a dividend.
IBO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
IBO stock is listed on the NYSE Arca exchange.
IMPACT BIOMEDICAL INC (IBO) operates in the Health Care sector and the Pharmaceuticals industry.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IBO.
Over the last trailing twelve months IBO reported a non-GAAP Earnings per Share(EPS) of -3.58. The EPS decreased by -509.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -201.86% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |